We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vernalis Announces Successful Study With CCP-01
News

Vernalis Announces Successful Study With CCP-01

Vernalis Announces Successful Study With CCP-01
News

Vernalis Announces Successful Study With CCP-01

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vernalis Announces Successful Study With CCP-01"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vernalis plc announces successful completion of the CCP-01 Pivotal Single Dose comparative bioavailability study.

CCP-01 is the first product being developed for Vernalis by Tris Pharma for the US prescription cough cold market. It will now move into a multi-dose comparative bioavailability study and continues in 12 month stability studies. Subject to the successful outcome of these studies, filing of the NDA for CCP-01 with the FDA remains on track to be made in mid-2014.

Under the deal announced in February 2012, Vernalis is paying Tris Pharma to develop up to six unique extended release equivalents to existing immediate release prescription cough cold treatments. The financial terms of this licensing deal are not disclosed.

Ian Garland, CEO of Vernalis commented "We are delighted with these results and the continued progression of this project and our collaboration with Tris".

Advertisement